



With 33% CAGR annual value creation since its IPO 20 years ago (over 296 times appreciation*) a study finds that Eurofins ranks first in value creation of all stocks listed in Europe since October 24, 1997**

24 October 2017

Eurofins Scientific (EUFI.PA), the world leader in bioanalytical testing, celebrates **20 years since the Group's Initial Public Offering (IPO)** on the 24th of October, 1997. Coinciding with the anniversary, the UK-based Marten & Co. independent research firm has published a detailed report examining Eurofins' value creation performance over the past 20 years.

Data from Marten & Co.'s research show that in the 20 years since its IPO, **Eurofins ranks highest in terms of its total returns to shareholders** (a TSR of 33.3% compounded annual growth rate or "CAGR") among all companies that were listed in Europe for the whole period, as well as compared to its publicly-listed peers in both the Testing, Inspection and Certification and the Healthcare sectors. Investors who have supported the Group have outperformed key benchmark indices (CAC 40, SBF 120 and S&P 500) by over 29% CAGR on average from October 1997 to October 2017*.

An investor having invested the equivalent of EUR 3,500 at Eurofins' IPO would have over **EUR 1 million** today including dividends received.

Eurofins' value creation track record over the last 20 years (based on CAGR of total shareholder return) is therefore comparable to stock market behemoths (Apple 32.5% and Amazon 29.8%). More importantly, Eurofins' internal stakeholders have also benefitted from its success, **with over 100 of the Group's leaders having accumulated in excess of EUR 1 million capital gains*** from the Company's Long Term Incentive (LTI) Stock Program in the last 20 years and over 200 more than EUR 500,000.**

The management of Eurofins believes that beyond the robust structural drivers supporting its businesses, the Group's singular focus on innovation and achieving market leadership in the few laboratory activities that have a direct positive impact on health rather than being very diversified has been one of its key success factors. This strategy has been reflected in significant long-term investments to ensure that Eurofins has the best laboratory network with the most state-of-the-art infrastructure and the most comprehensive analytical service portfolio to serve the food, environment and pharmaceutical sectors, as well as clinicians and healthcare providers. It is this relentless commitment to be the best and most innovative laboratory partner for our clients that has enabled Eurofins to grow by over 36% per year on average from EUR 6.6m of revenues in 1997 to EUR 2.5bn in 2016, creating a cumulative total shareholder return of 29,582% between 24 October 1997 and 10 October 2017.

Comment from **Dr. Gilles Martin**, Eurofins CEO: “The inherent value of our activities, both in terms of their positive impact on health, safety and the environment, and as reflected in the value we generate for our clients, our employees and all our stakeholders, drives our passion to continue to build a unique laboratory infrastructure and deliver the most innovative and best quality testing service to all our clients. It reinforces our commitment to remain true to our vision of becoming the **world leader in testing for life**, and our mission of **contributing to a safer and healthier world** by providing our customers with innovative and high quality laboratory and advisory services whilst creating opportunities for our employees and **generating sustainable shareholder value**.”

**Based on closing share price of 10th October 2017 – EUR 543.00*

***Source: Marten and Co.’s value creation study, 24th October 2017*

****Being the sum of pre-tax capital gains realized and potential gains on outstanding LTI Stock Program at reference share price as of 10th October 2017.*

For more information, please visit www.eurofins.com or contact:

Investor Relations
Eurofins Scientific
Phone: +32 2 766 1620
E-mail: ir@eurofins.com

Notes for the editor:

Eurofins – a global leader in bio-analysis

Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is the world leader in food, environment and pharmaceutical products testing and that it is also one of the global independent market leaders in certain testing and laboratory services for agrosience, genomics, discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 30,000 staff in 400 laboratories across 41 countries, Eurofins offers a portfolio of over 150,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.